身体成分变化对胃癌新辅助化疗疗效的研究进展

Research Progress on the Effect of Body Composition Changes on Neoadjuvant Chemotherapy for Gastric Cancer

当前,在我国,大部分胃癌病人在初次治疗时就已经被确诊为局部进展期或者晚期,尽管目前局部进展期胃癌病人的大部分治疗方式都还是以手术为主,但是新辅助化疗技术已逐渐成为了标准治疗模式的重要组成部分,合理的新辅助化疗技术可以改善局部进展期胃癌病人的预后。由于新辅助化疗本身就具有个体间的不同差异性,也因此造成了其效果的巨大差异,因此合理的效果预期可以改善治疗质量及减少个体经济成分,从而尽可能地减少癌症进一步发展,而高效精确地预估新辅助化疗效果也是目前亟待解决的临床难点。本文就身体不同成分变化与新辅助化疗的疗效关系的最新展望进行综述。

At present, in China, most patients with gastric cancer have been diagnosed as locally advanced or advanced at the time of initial treatment. Although most of the treatment methods of locally advanced gastric cancer patients are mainly still surgery, neoadjuvant chemotherapy technology has gradually formed an important part of the standard treatment mode. Reasonable neoadjuvant chemotherapy can improve the prognosis of patients with locally advanced gastric cancer. Neoadjuvant chemotherapy itself has different individual differences, which also leads to great differences in its effects. Therefore, reasonable effect expectation can improve the treatment quality and reduce individual economic components, so as to reduce the further development of cancer as much as possible. Efficient and accurate prediction of the effect of neoadjuvant chemotherapy is also a clinical difficulty to be solved. This paper reviews the latest prospect of the relationship between the changes of different body components and the efficacy of neoadjuvant chemotherapy.